A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 696 participants.

Also called NCT02414841

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 696 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02414841
Other papers using this trial's data
  • PATENCY-2 trial of vonapanitase to promote radiocephalic fistula use for hemodialysis and secondary patency The journal of vascular access, 2022-03 DOI, PubMed 33482699

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02414841. Randomized; quadruple masking; primary purpose treatment. Start 2015-08 (actual); primary completion 2018-02 (actual). Results posted on 2019-08-13.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)
Intervention (Drug)
Vonapanitase
Intervention (Drug)
Placebo
Lead sponsor
Proteon Therapeutics (class: industry)

Record details

Record id
cardio:ct-nct02414841
Content hash
ebc89396b72641fe2b98efcc6b3cebea6113ff02827bd6471c8c05eaabec48cd